Table 1 Patients’ baseline characteristics in the cFAS
Characteristics | Groups | |||
|---|---|---|---|---|
40 mg orally once daily (n = 3) | 80 mg orally once daily (n = 99) | 160 mg orally once daily (n = 23) | 240 mg orally once daily (n = 7) | |
Age, year, median (range) | 47 (44–55) | 60 (30–78) | 53 (39–67) | 55 (37–74) |
Sex | ||||
 Male, n(%) | 1 (33) | 41 (41) | 9 (39) | 2 (29) |
 Female, n(%) | 2 (67) | 58 (59) | 14 (61) | 5 (71) |
EGFR mutation subtype | ||||
 19Del, n(%) | 0 | 54 (55) | 12 (52) | 4 (57) |
 L858R, n(%) | 3 (100) | 42 (42) | 11 (48) | 3 (43) |
 19Del + L858R, n(%) | 0 | 1 (1) | 0 | 0 |
 Other, n(%)a | 0 | 2 (2) | 0 | 0 |
Number of CNS lesions | ||||
 1–3, n(%) | 2 (67) | 46 (46) | 8 (35) | 4 (57) |
 ≥ 4, n(%) | 1 (33) | 53 (54) | 15 (65) | 3 (43) |
CNS radiotherapy history, n(%) | 0 | 19 (19) | 3 (13) | 0 |
CNS surgery history, n(%) | 0 | 1 (1) | 0 | 0 |